UHS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Universal Health Services Inc (UHS) does not currently present a strong buy opportunity for a beginner, long-term investor with $50,000-$100,000 available. The technical indicators show bearish trends, options data suggests bearish sentiment, and analysts' ratings are mixed with a lack of strong upward momentum. While the company's financials in Q4 2025 showed solid growth, the stock's near-term price action and sentiment do not align with the investor's goals.
The technical indicators for UHS are bearish. The MACD histogram is negative and contracting, RSI is neutral at 29.538, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot point of 189.86, with support levels at 183.297 and 179.242, suggesting potential downside risk.
The company's Q4 2025 financials showed strong YoY growth: Revenue increased by 9.05%, Net Income by 34.16%, and EPS by 42.34%. Additionally, news of significant merger and acquisition activity in the sector could provide a long-term boost.
Analysts have mixed ratings, with some lowering price targets due to weak acute business performance and exposure to policy changes. Technical indicators are bearish, and options sentiment is negative. The stock also has a 60% chance to decline by 0.92% in the next day and 6.61% in the next month.
In Q4 2025, Universal Health Services reported strong financial growth: Revenue increased to $4.49 billion (up 9.05% YoY), Net Income rose to $445.94 million (up 34.16% YoY), and EPS increased to $7.06 (up 42.34% YoY). Gross margin remained stable.
Analyst ratings are mixed. UBS raised the price target to $320 with a Buy rating, while Cantor Fitzgerald and Wells Fargo lowered their targets to $229 and $212, respectively, with Neutral and Equal Weight ratings. BofA reiterated an Underperform rating despite raising the target to $215. Barclays remains optimistic with an Overweight rating and a target of $268.
